BioWorld

Dec. 9, 2005

View Archived Issues

Protherics Sends Sepsis Drug To AstraZeneca In $341M Deal

In its most significant deal to date, Protherics plc licensed rights to its late-stage sepsis drug candidate to AstraZeneca plc for a potential £195 million (US$341 million). (BioWorld Today) Read More

Feeling Lucentis Pressure, QLT Cuts Staff, Restructures

Read More

Synergistic With Velcade, NPI-0052 Heading To Clinic

Read More

Dyax Starts Pivotal Phase III With HAE Treatment DX-88

Read More

GTC Moving ATryn Forward Via Stock Deal Worth $16.7M

Read More

U.S. Patent Disclosures

Read More

Other News To Note

Read More